Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorder & Addiction Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRNB2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CHRNB2 Lentivirus Premade Particles. Full-length ORF with puromycin selection marker. Sequence Verified. For construction of heteromeric nAChR cell lines. | View CHRNB2 Products |
| Co-expression Antigen | CHRNA4 + CHRNB2 Dual Expression Lentivirus. Functional alpha4beta2 receptor complex. HEK293T packaging. High titer (>10^8 TU/ml). | View CHRNA4 Products |
| Mutant Library | CHRNB2 Epilepsy Mutants (V287L, V287M, T265I). Recombinant variants in expression vectors. Sequence Verified. | View CHRNB2 Products |
| Benchmark Ab | Anti-CHRNB2 Antibody (Epitope Mapping Control). Recombinant rabbit mAb. Sequence Verified. For Western/Flow validation. | View CHRNB2 Products |
| Validator | CHRNB2 siRNA Set (3 unique sequences). For specific knockdown verification in functional assays. Endotoxin controlled. | View CHRNB2 Products |
| Related Target: CHRNA4 | Forms high-affinity alpha4beta2 receptor with CHRNB2. Primary functional partner. | View CHRNA4 Products |
| Related Target: CHRNB4 | Alternative beta subunit for alpha3beta4 composition. Counter-screening essential for avoiding autonomic side effects. | View CHRNB4 Products |
| Related Target: CHRNA7 | Homomeric nAChR target for cognitive enhancement and orthogonal screening. | View CHRNA7 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Transmembrane Conformation | Lentivirus-mediated stable expression in HEK293/CHO ensures native ion channel assembly. Sequence Verified. |
| Heteromeric Assembly Validation (alpha4beta2 vs alpha3beta2) | Dual-promoter lentivirus expressing stoichiometric CHRNA4/CHRNB2; HEK293 expressed (native glycosylation). |
| Epilepsy-associated Mutant Functional Profiling | Site-specific mutant proteins (V287L, V287M, T265I); High purity (>95%); SDS-PAGE confirmed. |
| Subtype Selectivity Screening (neuronal vs muscle nAChR) | Ortholog panel: Human/Mouse/Rat/Cyno CHRNB2 proteins available; Endotoxin <1 EU/ug. |
| Specificity Controls | Validated siRNA for knockdown confirmation; Benchmark antibodies for assay standardization. |
Live CHRNB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Receptor Research
- ➤ Recent Patent Filings
- ➤ Resistance Research
Global Clinical Landscape & Future Outlook
The development of CHRNB2 modulators is critical for central nervous system (CNS) indications, including smoking cessation, depression, cognitive impairment (Alzheimer's and Parkinson's disease), and epilepsy (ADNFLE). Historically dominated by small molecule partial agonists (e.g., varenicline), the field is now shifting toward highly selective Positive Allosteric Modulators (PAMs) that enhance endogenous cholinergic signaling without causing receptor desensitization. Future R&D will rely on subtype-selective modulation to discriminate beta2- vs beta4-containing receptor populations to minimize off-target cardiovascular effects. Precision neuroscience approaches targeting specific CHRNB2 mutations (V287L, V287M, T265I) are emerging for epilepsy.
Key Disease-Associated Mutations
The following mutations in CHRNB2 are linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) and altered receptor function:
| dbSNP ID | Mutation (Protein) | Functional Effect | Evidence |
|---|---|---|---|
| rs74315291 | V287L (ENFL3) | Reduced Ca²⁺ dependence; increased seizure susceptibility | UniProt VAR_012714 |
| rs7 | ~10-fold increase in ACh sensitivity | Enhanced channel opening; gain-of-function | UniProt VAR_012715 |
| rs55685423 | Mutation under study | Likely affects channel gating | UniProt VAR_021564 |
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Partial/Selective Agonist) | Pfizer, Achieve Life Sciences, Preclinical Academia | Nicotine Dependence, Alzheimer's Cognitive Deficit | Heteromeric cell line (Lentivirus stable expression for alpha4beta2 selectivity) |
| Positive Allosteric Modulators (PAM/NAM) | AbbVie, NeuroSearch, Biotech Discovery | Cognitive Deficits (AD, Schizophrenia), Epilepsy (ADNFLE) | Mutant protein panel (Epilepsy variants V287L/M for mechanism validation) |
| Targeted Degradation | Emerging Biotech | CNS Disorders | Knockdown validation (high-efficiency siRNA) |
| Antibody Therapeutics | Emerging Biotech | Autoimmune (Myasthenia variants) | ECD-Fc fusion proteins (high purity >95%) |